# Umbilical Cord Mesenchymal Stem Cells and Liraglutide in Diabetes Mellitus

Study · id `cardio:ct-nct01954147` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01954147](<https://clinicaltrials.gov/study/NCT01954147>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT01954147

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 1/2 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 100 participants.

## Technical summary

Registry record NCT01954147. Non-randomized; no masking; primary purpose treatment. Start 2013-10 (registry gives no type); primary completion 2014-10 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; non-randomized; no masking; primary purpose treatment
- Phase: Phase 1/2
- Enrolled: 100 participants (planned count; ClinicalTrials.gov record NCT01954147, source copy `cardio:ctgov-nct01954147-2014-02-20`, retrieved 2026-10-26)
- Start date: 2013-10 (registry gives no type) (ClinicalTrials.gov record NCT01954147, source copy `cardio:ctgov-nct01954147-2014-02-20`, retrieved 2026-10-26)
- Primary completion: 2014-10 (anticipated) (ClinicalTrials.gov record NCT01954147, source copy `cardio:ctgov-nct01954147-2014-02-20`, retrieved 2026-10-26)
- Completion: 2015-10 (anticipated) (ClinicalTrials.gov record NCT01954147, source copy `cardio:ctgov-nct01954147-2014-02-20`, retrieved 2026-10-26)
- Countries: China (ClinicalTrials.gov record NCT01954147, source copy `cardio:ctgov-nct01954147-2014-02-20`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01954147-2014-02-20`, retrieved 2026-10-26)

## The registry's words

- Brief title: Umbilical Cord Mesenchymal Stem Cells and Liraglutide in Diabetes Mellitus
- Condition: Type 2 Diabetes
- Intervention (Drug): GLP-1
- Intervention (Biological): SC
- Intervention (Other): Standard Medical Treatment
- Lead sponsor: Diabetes Care Center of Nanjing Military Command
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: \[The effect of liraglutide in combination with human umbilical cord mesenchymal stem cells treatment on glucose metabolism and β cell function in type 2 diabetes mellitus\] (`cardio:pubmed-27143183`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: e9e24d6787d1cdb3b9e98501c51fe82489a2ffa2785fa33d7a55c489f7f8fec9
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
